Press Release | October 22, 2026
Sundance Biosciences Announces First Patient Dosed in U.S. Phase 2 Clinical Trial of SUN-627 for Progressive Forms of Multiple Sclerosis (MS)
Read More
Press Release | October 21, 2026
Sundance Biosciences Announces Presentation of Phase 1 Results for SUN-627, a Brain-Penetrant TYK2 Inhibitor for the Treatment of Multiple Sclerosis (MS)
Read More
Press Release | October 21, 2026
Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson’s Disease
Read More
Press Release | October 13, 2026
āshibio Presents Preliminary Efficacy Data for Andecaliximab Demonstrating an 86.2% Reduction in New Flare-Up Rate in Patients with FOP
Read More
